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Levamisole is an effective immunomodulator
for patients with oral lichen planusAfter reading the articles “Modulation of serum anti-
thyroglobulin and anti-thyroid microsomal autoantibody
levels by levamisole in patients with oral lichen planus” and
“Modulation of serum antinuclear antibody levels by leva-
misole treatment in patients with oral lichen planus”,
which were published in the March and May 2011 issues of
Journal of the Formosan Medical Association, respec-
tively,1,2 we found that levamisole is an effective immu-
nomodulator for patients with oral lichen planus (OLP). In
the former paper, the authors showed significantly higher
frequencies of serum antithyroglobulin autoantibody (TGA)
and antithyroid microsomal autoantibody (TMA) levels in
Taiwanese OLP patients than in healthy controls. These
serum TGA and TMA levels can be reduced partially or
become undetectable in approximately 88% of TGA-positive
and 96% of TMA-positive OLP patients after one year of
levamisole treatment.1 In the latter paper, the authors
demonstrated a significantly higher frequency (23.2%) of
serum antinuclear antibody in Taiwanese OLP patients than
in healthy controls. Treatment with levamisole for 2 to 38
months reduces the high serum antinuclear antibody to an
undetectable level, and significantly improves the signs and
symptoms in all treated OLP patients.2
Levamisole was first introduced as an anthelmintic in
human and veterinary medicine. There is some indication
that levamisole may be useful by itself as an adjuvant
therapy for resected melanoma. It has also been shown to
be effective in combination with 5-fluorouracil as adjuvant
therapy for tumor-node-metastasis stage III (Dukes’ C)
colon carcinoma.3 Levamisole seems to regulate cell
mediated immune reactions by restoring effector functions
of peripheral T-lymphocytes and phagocytes and by0929-6646/$ - see front matter Copyright ª 2012, Elsevier Taiwan LLC
http://dx.doi.org/10.1016/j.jfma.2012.09.003stimulating precursor T-lymphocyte to differentiate into
mature cells.4 Therefore, we suggest that the authors may
need to examine the number and function of CD4, CD8, and
activated T cells in the peripheral blood of OLP patients in
order to understand the immunomodulating effect of
levamisole on T cells.
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